A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats

Psychopharmacology

Volumn 217, Issue 2, 2011, Pages 153-166

  Harris, Andrew C ^a,b,c   Pentel, Paul R ^a,b,c   Burroughs, Danielle ^a   Staley, Mylissa D ^a   LeSage, Mark G ^a,b,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Compensation; Intracranial selfstimulation; Nicotine; Self administration; Tobacco harm reduction; Withdrawal

Indexed keywords

SODIUM CHLORIDE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INFUSION; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; HARM REDUCTION; INTRACRANIAL SELF STIMULATION THRESHOLD; MALE; NICOTINE WITHDRAWAL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; EXTINCTION, PSYCHOLOGICAL; INFUSION PUMPS, IMPLANTABLE; MALE; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SENSORY THRESHOLDS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 82955235544     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2273-9     Document Type: Article

References (71)

1. Ahmed SH, Kenny PJ, Koob GF, Markou A (2002) Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 5:625-626 (Pubitemid 34742974)
2. Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36:597-613 (Pubitemid 26168710)
3. Benowitz NL (2008) Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 83:531-541 (Pubitemid 351417076)
4. Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd (2009) Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomark Prev 18:876-883
5. Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd (2007) Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomark Prev 16:2479-2485 (Pubitemid 351196384)
6. Benowitz NL, Henningfield JE (1994) Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 331:123-125 (Pubitemid 24202231)
7. Benowitz NL, Jacob P 3rd, Bernert JT, Wilson M, Wang L, Allen F, Dempsey D (2005) Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomark Prev 14:1376-1383 (Pubitemid 40807334)
8. Benowitz NL, Jacob P 3rd, Herrera B (2006) Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 80:703-714 (Pubitemid 44920221)
9. Benowitz NL, Jacob P 3rd, Kozlowski LT, Yu L (1986) Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med 315:1310-1313 (Pubitemid 17030407)
10. Britton J, Edwards R (2008) Tobacco smoking, harm reduction, and nicotine product regulation. Lancet 371:441-445 (Pubitemid 351173299)
11. Brower VG, Fu Y, Matta SG, Sharp BM (2002) Rat strain differences in nicotine self-administration using an unlimited access paradigm. Brain Res 930:12-20 (Pubitemid 34195623)
12. Chaudhri N, Caggiula AR, Donny EC, Booth S, Gharib M, Craven L, Palmatier MI, Liu X, Sved AF (2006) Operant responding for conditioned and unconditioned reinforcers in rats is differentially enhanced by the primary reinforcing and reinforcementenhancing effects of nicotine. Psychopharmacology 189:27-36 (Pubitemid 44607257)
13. Cohen A, Young RW, Velazquez MA, Groysman M, Noorbehesht K, Ben-Shahar OM, Ettenberg A (2009) Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict. Psychopharmacology 204:541-549
14. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11-20
15. Corrigall WA, Coen KM (1989) Nicotine maintains robust selfadministration in rats on a limited-access schedule. Psychopharmacology 99:473-478 (Pubitemid 19273101)
16. DeNoble VJ, Mele PC (2006) Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology 184:266-272 (Pubitemid 43255842)
17. Donny EC, Caggiula AR, Knopf S, Brown C (1995) Nicotine selfadministration in rats. Psychopharmacology 122:390-394
18. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A, Maldovan V, Shupenko C, McCallum SE (1999) Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology 147:135-142 (Pubitemid 30010560)
19. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76-79 (Pubitemid 28240257)
20. Epstein DH, Preston KL, Stewart J, Shaham Y (2006) Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology 189:1-16 (Pubitemid 44607255)
21. Harris AC, Burroughs D, Pentel PR, LeSage MG (2008) Compensatory nicotine self-administration in rats during reduced access to nicotine: an animal model of smoking reduction. Exp Clin Psychopharmacol 16:86-97 (Pubitemid 351313947)
22. Harris AC, Mattson C, LeSage MG, Keyler DE, Pentel PR (2010) Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol Biochem Behav 96:217-227
23. Harris AC, Pentel PR, LeSage MG (2007) Prevalence, magnitude, and correlates of an extinction burst in drug-seeking behavior in rats trained to self-administer nicotine during unlimited access (23 h/ day) sessions. Psychopharmacology 194:395-402 (Pubitemid 47389348)
24. Harris AC, Pentel PR, LeSage MG (2009) Correlates of individual differences in compensatory nicotine self-administration in rats following a decrease in nicotine unit dose. Psychopharmacology 205:599-611
25. Hatsukami DK, Henningfield JE, Kotlyar M (2004) Harm reduction approaches to reducing tobacco-related mortality. Ann Rev Public health 25:1-19
26. Hatsukami DK, Joseph AM, Lesage M, Jensen J, Murphy SE, Pentel PR, Kotlyar M, Borgida E, Le C, Hecht SS (2007) Developing the science base for reducing tobacco harm. Nicotine Tob Res 9 (Suppl 4):S537-553
27. Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG,Murphy SE, Stepanov I, Hecht SS (2010a) Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 105:343-355
28. Hatsukami DK, Le CT, Zhang Y, Joseph AM, Mooney ME, Carmella SG, Hecht SS (2006) Toxicant exposure in cigarette reducers versus light smokers. Cancer Epidemiol Biomark Prev 15:2355-2358 (Pubitemid 46048290)
29. Hatsukami DK, Perkins KA, Lesage MG, Ashley DL, Henningfield JE, Benowitz NL, Backinger CL, Zeller M (2010b) Nicotine reduction revisited: science and future directions. Tob Control 19: e1-10
30. Hecht SS, Murphy SE, Carmella SG, Zimmerman CL, Losey L, Kramarczuk I, Roe MR, Puumala SS, Li YS, Le C, Jensen J, Hatsukami DK (2004) Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst 96:107-115 (Pubitemid 38195901)
31. Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD (1998) Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control 7:281-293 (Pubitemid 128656171)
32. Hughes JR (2007) Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 9:329-339 (Pubitemid 46404265)
33. Hughes JR, Carpenter MJ (2005) The feasibility of smoking reduction: an update. Addiction 100:1074-1089 (Pubitemid 41113601)
34. Joseph AM, Hecht SS, Murphy SE, Lando H, Carmella SG, Gross M, Bliss R, Le CT, Hatsukami DK (2008) Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tob Res 10:471-481 (Pubitemid 351385828)
35. Kenny PJ, Chartoff E, Roberto M, Carlezon WA Jr, Markou A (2009) NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 34:266-281
36. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006) Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26:5894-5900 (Pubitemid 44318354)
37. Kenny PJ, Markou A (2006) Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology 31:1203-1211 (Pubitemid 43971837)
38. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473-2476 (Pubitemid 10249276)
39. LeSage MG, Keyler DE, Collins G, Pentel PR (2003) Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and selfadministered nicotine doses and serum concentrations. Psychopharmacology 170:278-286 (Pubitemid 37491607)
40. LeSage MG, Keyler DE, Shoeman D, Raphael D, Collins G, Pentel PR (2002) Continuous nicotine infusion reduces nicotine selfadministration in rats with 23-h/day access to nicotine. Pharmacol Biochem Behav 72:279-289 (Pubitemid 34251337)
41. Lynch WJ, Carroll ME (1999) Regulation of intravenously selfadministered nicotine in rats. Exp Clin Psychopharmacol 7:198-207 (Pubitemid 29399022)
42. Malin DH (2001) Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 70:551-559 (Pubitemid 34131648)
43. Markou A, Koob GF (1991) Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4:17-26
44. Markou A, Koob GF (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51:111-119
45. Markou A, Paterson NE (2001) The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 3:361-373 (Pubitemid 33101063)
46. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF (1993) Animal models of drug craving. Psychopharmacology 112:163-182 (Pubitemid 23278275)
47. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190:269-319 (Pubitemid 46156883)
48. O'Dell LE, Bruijnzeel AW, Smith RT, Parsons LH, Merves ML, Goldberger BA, Richardson HN, Koob GF, Markou A (2006) Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology 186:612-619 (Pubitemid 43855849)
49. O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, Markou A, Zorrilla EP, Koob GF (2007) Extended access to nicotine self-administration leads to dependence: circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320:180-193 (Pubitemid 46025733)
50. Paterson NE, Balfour DJ, Markou A (2008) Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob Res 10:995-1008 (Pubitemid 351998436)
51. Paterson NE, Froestl W, Markou A (2004) The GABAB receptor agonists baclofen and CGP44532 decreased nicotine selfadministration in the rat. Psychopharmacology 172:179-186 (Pubitemid 38388767)
52. Paterson NE, Markou A (2004) Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology 173:64-72 (Pubitemid 38591148)
53. Piasecki TM, Fiore MC, Baker TB (1998) Profiles in discouragement: two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol 107:238-251 (Pubitemid 28237487)
54. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB (2003) Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations. J Abnorm Psychol 112:14-27 (Pubitemid 36249840)
55. Roiko SA, Harris AC, LeSageMG, Keyler DE, Pentel PR (2009) Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol Biochem Behav 93:105-111
56. Rose J, Behm F (2004) Effects of low nicotine content cigarettes on smoke intake. Nicotine Tob Res 6:309-319 (Pubitemid 38678861)
57. Rose JE, Corrigall WA (1997) Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 130:28-40 (Pubitemid 27107782)
58. Scherer G (1999) Smoking behaviour and compensation: a review of the literature. Psychopharmacology 145:1-20 (Pubitemid 29339758)
59. Shiffman S, Gitchell JG, Warner KE, Slade J, Henningfield JE, Pinney JM (2002) Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res 4 (Suppl 2):S113-129 (Pubitemid 36104368)
60. Shoaib M, Schindler CW, Goldberg SR (1997) Nicotine selfadministration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology 129:35-43 (Pubitemid 27037448)
61. Spiller K, Xi ZX, Li X, Ashby CR Jr, Callahan PM, Tehim A, Gardner EL (2009) Varenicline attenuates nicotine-enhanced brainstimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology 57:60-66
62. Stead LF, Lancaster T (2007) Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev: CD005231
63. Stratton K, Shetty P, Wallace R, Bondurant S (2001) Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control 10:189-195 (Pubitemid 33720586)
64. U.S. DHHS (1999) Nicotine addiction: health consequences of smoking. U.S. Department of Health and Human Services
65. Valentine JD, Hokanson JS, Matta SG, Sharp BM (1997) Selfadministration in rats allowed unlimited access to nicotine. Psychopharmacology 133:300-304 (Pubitemid 27445664)
66. Watkins SS, Epping-Jordan MP, Koob GF, Markou A (1999) Blockade of nicotine self administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 62:743-751 (Pubitemid 29127180)
67. Watkins SS, Koob GF, Markou A (2000a) Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19-37
68. Watkins SS, Stinus L, Koob GF, Markou A (2000b) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292:1053-1064 (Pubitemid 30136601)
69. West RJ, Russell MA, Jarvis MJ, Feyerabend C (1984) Does switching to an ultra-low nicotine cigarette induce nicotine withdrawal effects? Psychopharmacology 84:120-123 (Pubitemid 14032223)
70. Zacny JP, Stitzer ML (1988) Cigarette brand-switching: effects on smoke exposure and smoking behavior. J Pharmacol Exp Ther 246:619-627
71. Zeller M, Hatsukami D (2009) The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control 18:324-332